Chandrikha Chandrasekharan, MBBS - NETRF

Dr. Chandrikha Chandrasekharan, MBBS

Claim this profile

University of Iowa/Holden Comprehensive Cancer Center

Studies Pancreatic Cancer
Studies Lung Cancer
17 reported clinical trials
40 drugs studied

Area of expertise

1

Pancreatic Cancer

Chandrikha Chandrasekharan, MBBS has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
Stage III
PD-L1 positive
2

Lung Cancer

Chandrikha Chandrasekharan, MBBS has run 5 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

University Of Iowa/Holden Comprehensive Cancer Center

Image of trial facility.

University Of Iowa Healthcare Cancer Services Quad Cities

Clinical Trials Chandrikha Chandrasekharan, MBBS is currently running

Image of trial facility.

SGN-EGFRd2

for Advanced Cancer

This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.

Recruiting

1 award

Phase 1

3 criteria

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about Chandrikha Chandrasekharan, MBBS

Clinical Trial Related

6 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Chandrikha Chandrasekharan, MBBS has experience with

  • Gallium-68 Pentixafor
  • Surufatinib
  • Tislelizumab
  • SY-5609
  • Fulvestrant
  • Nab-paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Chandrikha Chandrasekharan, MBBS specialize in?

Is Chandrikha Chandrasekharan, MBBS currently recruiting for clinical trials?

Are there any treatments that Chandrikha Chandrasekharan, MBBS has studied deeply?

What is the best way to schedule an appointment with Chandrikha Chandrasekharan, MBBS?

What is the office address of Chandrikha Chandrasekharan, MBBS?

Is there any support for travel costs?